Streetbeat News

Stock Prices

NTLA

Intellia Therapeutics announced that a single dose of NTLA-2002 led to a 98% mean reduction in monthly hereditary angioedema (HAE) attack rates, with an average follow-up of over 20 months. The data, presented at the EAACI Congress 2024, showed that 8 out of 10 patients remained attack-free and all patients who discontinued prophylaxis treatment remained free of chronic prophylaxis. The therapy demonstrated a favorable safety and tolerability profile.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:38 pm

GILD

RCUS

Gilead Sciences and Arcus Biosciences announced that their combination therapy significantly reduced the risk of death and disease progression in third-line metastatic colorectal cancer patients in a Phase 1b/2 trial. The results will be presented at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:36 pm

AZN

AstraZeneca announced that its drug Imfinzi significantly reduces the risk of death by 27% compared to placebo in a global Phase III trial for limited-stage small cell lung cancer. The trial results showed a 57% survival rate at three years and will be presented at the 2024 ASCO Annual Meeting.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:16 pm

ARKB

BLK

HOOD

Cathie Wood's Ark Investment Management has withdrawn its plans for a spot-Ether ETF to focus on a spot Bitcoin ETF instead. The ARK 21Shares Bitcoin ETF ranks fourth in assets, trailing BlackRock's iShares Bitcoin Trust. The SEC has approved filings for spot-Ether ETFs, but issuers still need further approval. Ark's Bitcoin ETF saw a significant outflow recently.

Portfolio Pulse from Bibhu Pattnaik

June 02, 2024 | 2:15 pm

ALXO

ALX Oncology Holdings Inc. (NASDAQ: ALXO) presented promising Phase 1 ASPEN-07 clinical trial data at the 2024 ASCO Annual Meeting, showing tumor reduction in the majority of evaluable patients with advanced bladder cancer.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:13 pm

PBYI

Puma Biotechnology (NASDAQ:PBYI) presented findings from a Phase II study of alisertib in endocrine-resistant metastatic breast cancer at the ASCO 2024 Annual Meeting. The study showed promising clinical activity and a tolerable safety profile.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:03 pm

CLDX

Celldex Therapeutics (NASDAQ:CLDX) announced positive Phase 2 trial results for barzolvolimab, showing significant improvement in angioedema symptoms in patients with chronic spontaneous urticaria (CSU) after 12 weeks.

Portfolio Pulse from Charles Gross

June 02, 2024 | 2:01 pm

AAPL

AMD

NVDA

PLTR

This week in AI, Nvidia is closing the market cap gap with Apple, Ark Invest made significant trades in AMD, Palantir, and Moderna, and AI's future in smartphones looks promising. Nvidia's stock surged 127% in five months, while Apple's gained 3.6%.

Portfolio Pulse from Benzinga Neuro

June 02, 2024 | 1:02 pm

AAPL

The past week in the tech world saw Elon Musk mocking Apple, Apple striking a deal with OpenAI, plans to revamp Siri, issues with iPhone 16 Pro Max screens, and the expected launch of the first OLED MacBook Pro in 2026.

Portfolio Pulse from Benzinga Neuro

June 02, 2024 | 12:30 pm

PEPECOINUSD

PEPEUSD

RNDRUSD

A well-known crypto trader, Altcoin Sherpa, has forecasted substantial growth for two meme coins, Pepe (PEPE) and Pepe Coin, despite short-term pullbacks. He also expressed long-term bullishness on Render (RNDR), advising a dollar-cost averaging strategy. The predictions highlight the volatility and speculative nature of meme coins and the growing interest in decentralized technologies.

Portfolio Pulse from Bibhu Pattnaik

June 01, 2024 | 5:53 pm